FutureChemistry
FutureChemistry is a Netherlands-based boutique consultancy that industrializes radiopharmaceutical and medical isotope production processes, serving European drug developers and isotope producers with custom equipment design, automation, validation, and CMC/QA services.
- Company typePrivate
- Founded2007
- HeadquartersWageningen, Netherlands
- Headcount1–10
- GTM typeB2B
- OfferingServices
What FutureChemistry does
FutureChemistry Holding BV is a privately held boutique consultancy headquartered in Wageningen, the Netherlands, founded in 2007 and operating with fewer than 10 staff plus a three-member advisory board. The firm industrializes radiochemical and radiopharmaceutical innovations, supporting radiopharmaceutical developers, medical isotope producers, and pharmaceutical companies entering nuclear medicine across Europe. Its service portfolio spans four integrated lines: custom equipment design and engineering, process development and automation, commissioning/qualification/validation, and Chemistry, Manufacturing and Controls (CMC) plus Quality Assurance strategy. The company's flagship proprietary product is the CISSPECT Desk-Lab, a modular automated radiopharmaceutical synthesiser for controlled chemical synthesis.
Underlying the service offering is deep expertise in flow chemistry applied to radiochemical and radiopharmaceutical production, with a particular emphasis on translating bench-scale reactions into automated, cGMP-aligned processes. The team is composed of PhD-level radiochemists and an industry veteran CMC/GMP consultant (formerly in senior QA roles at Bayer), giving the firm regulatory-grade credibility. The firm is ISO 9001 certified, operates independently of any equipment manufacturer, and uniquely does not assert claims on client-developed intellectual property — a positioning feature for risk-averse buyers in a regulated industry.
FutureChemistry generates revenue primarily through professional-services engagements (consultancy, process development, validation, CMC/QA), supplemented by custom hardware/equipment builds and sales of the CISSPECT Desk-Lab platform. Go-to-market is sales-led and event-driven: the CEO maintains an active LinkedIn presence, the firm attends industry conferences such as EANM 2025 in Barcelona, and a free, obligation-free initial consultation serves as the lead-conversion mechanism. No external funding rounds or institutional investors have been disclosed.
FutureChemistry firmographics
Firmographics- Name
- FutureChemistry
- Legal name
- FutureChemistry Holding BV
- Website
- https://futurechemistry.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- FutureChemistry is a Netherlands-based boutique consultancy that industrializes radiopharmaceutical and medical isotope production processes, serving European drug developers and isotope producers with custom equipment design, automation, validation, and CMC/QA services.
- Ownership category
- akta.pro rank
FutureChemistry industry classification
Industry- Product category
- Radiopharmaceutical Process Consulting
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC) (EUAKAIAC)
Keywords
Where FutureChemistry is headquartered
LocationHeadquarters
- HQ city
- Wageningen
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
FutureChemistry business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Consultancy Services: Boutique consultancy providing expertise in designing and building equipment, validating processes, and developing quality strategies in the radiopharmaceutical industry. Revenue derived from professional consulting engagements.
- Equipment Design and Engineering: Custom equipment design and build services for radiopharmaceutical processes, including systems for medical isotope purification and radiopharmaceutical manufacturing.
- CMC and QA Services: Broad spectrum of Chemistry, Manufacturing and Controls services from equipment and process design to technology transfer and manufacturing support for clinical trials.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Initial Consultation |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
FutureChemistry product offering
Product offeringCore offering
FutureChemistry is a boutique consultancy specializing in developing equipment, processes, and quality strategies in the radiopharmaceutical industry. The company provides custom solutions spanning from concept to clinic, including equipment design and engineering, process development and automation, commissioning and validation, and CMC & QA services for radiopharmaceutical and medical isotope production. Its core physical product is the CISSPECT Desk-Lab, a modular automated radiopharmaceutical synthesiser.
Product overview
FutureChemistry is a boutique consultancy specialising in the radiopharmaceutical industry, offering an integrated portfolio of services spanning equipment design and engineering, process development and automation, commissioning and validation, and CMC and QA services. The company provides the Cisspect Desk-Lab automated radiopharmaceutical synthesiser as its core product, alongside custom engineering solutions for medical isotope purification and radiopharmaceutical manufacturing. All services are designed to advance radiochemical and radiopharmaceutical innovations from concept to clinic, supporting clients throughout Europe.
Differentiator
Problem solved
Functional benefit
Products and services
- CISSPECT Desk-Lab Modular automated chemical synthesis system (automated radiopharmaceutical synthesiser) designed for radiopharmaceutical production processes. It enables controlled chemical synthesis of radiopharmaceuticals and serves radiopharmaceutical manufacturers and researchers.
- Equipment Design and Engineering Custom equipment design and engineering services for radiopharmaceutical processes, including systems for purification of medical isotopes and manufacturing of radiopharmaceuticals. Designed and built based on individual client needs.
- Process Development and Automation Development of new processes and automation of existing processes for radiopharmaceutical manufacturing, maximising efficiency and reliability. Targets radiopharmaceutical companies and medical isotope producers.
- Commissioning, Validation and Documentation Commissioning, qualification, and validation services ensuring smooth implementation of radiopharmaceutical processes. Supports clients through documentation and regulatory readiness.
- CMC & QA Services Chemistry, Manufacturing and Controls strategy services supporting cGMP-compliant operations for medical isotopes and radiopharmaceuticals. Covers equipment and process design, technology transfer, and manufacturing support for clinical trials.
Quantifiable outcome
- Advancing radiochemical and radiopharmaceutical innovations from concept to clinic
Companies that use FutureChemistry
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
FutureChemistry technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
FutureChemistry partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- VU University Medical CentrecoreDion van der Born performed PhD research at VU University Medical Centre, developing novel methodology for incorporating fluorine-18 labelled trifluoromethyl functional groups onto aromates. This represents a foundational research partnership for the company's radiochemistry expertise.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
FutureChemistry competitors and assessment
Company assessmentDirect peers
- Trasis: Belgium-based company specializing in automated synthesis modules and quality control equipment for radiopharmaceutical production. Direct peer as both design and supply hardware/software solutions for radiochemistry synthesis and purification, serving the same radiopharma and medical isotope customer base across Europe.
- Raytest: Germany-based specialist in radio-TLC, radio-HPLC, and radiochemistry measurement instruments for PET and radiopharmaceutical applications. Closely comparable as a focused instrumentation and tools provider for radiochemistry workflows, serving overlapping customers in European research institutes and radiopharma companies.
Broad incumbents
- GE HealthCare (Radiopharma Solutions): Global medical technology incumbent offering integrated radiopharma manufacturing equipment, CDMO services, and isotope production across PET and SPECT modalities. Broad incumbent overlapping with FutureChemistry in custom equipment design and GMP-compliant radiopharma process development, but at vastly greater scale.
- Siemens Healthineers (PETNET Solutions): Operates one of the largest radiopharma manufacturing networks globally, offering PET tracer production and distribution services. Overlaps with FutureChemistry in process industrialization and GMP-compliant manufacturing, but as part of a much larger diagnostics and imaging portfolio.
- IBA Radiopharma Solutions: Belgian-listed company providing cyclotrons, integrated PET radiopharma solutions, and contract manufacturing. Comparable to FutureChemistry in custom radiochemistry equipment and process development, but with significantly greater capital and global reach.
- Eckert & Ziegler: German-based radiopharma services and isotope production company offering contract manufacturing, equipment, and radioisotope distribution. Overlaps with FutureChemistry in radiopharmaceutical process equipment and GMP-compliant production services, but at substantially larger scale.
- Curium Pharma: Global radiopharmaceutical CDMO and manufacturer serving diagnostic and therapeutic nuclear medicine markets. Comparable as a GMP-compliant contract manufacturer for radiopharmaceuticals, but at vastly greater scale and as part of integrated commercial manufacturing rather than boutique consulting.
- Advanced Accelerator Applications (Novartis): Novartis-owned radioligand therapy pioneer (Lutathera, Pluvicto) with extensive manufacturing infrastructure for therapeutic radiopharmaceuticals. Overlaps with FutureChemistry in process industrialization and GMP manufacturing, but as part of a global pharma-backed operation.
Emerging players
- Comecer: Italian manufacturer of shielded cells, hot cells, and radiopharmaceutical manufacturing isolators. Comparable as a European supplier of specialized equipment for radiopharmaceutical production, though more focused on shielding/infrastructure than synthesis automation like FutureChemistry.
- Tema Sinergie: Italian supplier of radiochemistry synthesis modules, dose calibrators, and radiopharma production equipment. Closely comparable niche player providing automated synthesis systems for PET and therapeutic radiopharmaceuticals, targeting similar European customers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
FutureChemistry social profiles
Digital presenceFutureChemistry compliance and trust
Trust signalCompliance1 record
FutureChemistry financial estimates
Financial estimateRevenue estimate
Valuation estimate
FutureChemistry leadership team
Management profileNumber of profiles
Profiles4 records
FutureChemistry funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
FutureChemistry M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about FutureChemistry
What does FutureChemistry do?
FutureChemistry is a boutique consultancy specializing in developing equipment, processes, and quality strategies in the radiopharmaceutical industry. The company provides custom solutions spanning from concept to clinic, including equipment design and engineering, process development and automation, commissioning and validation, and CMC & QA services for radiopharmaceutical and medical isotope production. Its core physical product is the CISSPECT Desk-Lab, a modular automated radiopharmaceutical synthesiser.
Is FutureChemistry a public or private company?
FutureChemistry is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was FutureChemistry founded?
FutureChemistry was founded in 2007. It employs 1 to 10 people.
Where is FutureChemistry based?
FutureChemistry is headquartered in Wageningen, Netherlands, in the Europe region.
How does FutureChemistry make money?
Three revenue lines are on record. Consultancy Services are the primary driver. The others are equipment Design and Engineering and CMC and QA Services.
Who are FutureChemistry's main competitors?
Direct peers on record are Trasis and Raytest. Broad incumbents are GE HealthCare (Radiopharma Solutions), Siemens Healthineers (PETNET Solutions), IBA Radiopharma Solutions, Eckert & Ziegler, Curium Pharma and Advanced Accelerator Applications (Novartis). Emerging players are Comecer and Tema Sinergie.
Does FutureChemistry have an API?
No public API is recorded for FutureChemistry.
What industry is FutureChemistry in?
FutureChemistry's product category is Radiopharmaceutical Process Consulting. Its primary akta.pro industry code is EUAKAIAC, Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC). Its NAICS code is 334516 and its SIC code is 8731.